Lenalidomide promotes melarsoprol-activated cGAS-STING-mediated immunotherapy for hepatocellular carcinoma
KeAi Communications Co., Ltd.Peer-Reviewed Publication
Targeting the issue of immunosuppression in the tumor microenvironment (TME) during hepatocellular carcinoma (HCC) immunotherapy, this study was the first to confirm that melarsoprol (MEL), an arsenic-containing drug, activates the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway in tumor cells and induces an antitumor immune response . However, high-dose MEL excessively activates the pro-tumorigenic cytokine tumor necrosis factor-α (TNF-α), which impairs the immunotherapeutic efficacy. To address this, a poly(D,L-lactic-co-glycolic acid) (PLGA)-based nanoparticle (NP) was prepared in this study for the co-delivery of MEL and lenalidomide (LEN), a TNF-α inhibitor. Through erythrocyte membrane camouflage and aminoethyl anisamide (AEAA)-targeted modification, the nanoparticle was precisely enriched in HCC tissues. It significantly reversed the immunosuppressive TME and achieved antitumor effects in two mouse models of HCC . This study provides a novel strategy for the chemoimmunotherapy of HCC.
- Journal
- Fundamental Research
- Funder
- National Natural Science Foundation of China, Siming Scholar from Shanghai Shuguang Hospital, Youth Tip-top Talent Program from Shanghai Municipal Commission of Health, Constant-eminent Program from Shanghai Municipal Commission of Health, Xinglin Youth Scholar from Shanghai University of Traditional Chinese Medicine, Norman Bethune Program of Jilin University, China